2248
M. M. Sarmah et al.
LETTER
Caranfa, M. J.; Holden, K. G.; Jakas, D. R.; Gallagher, G.;
Mattern, M. R.; Mong, S. M.; Bartus, J. O.; Johnson, R. K.;
Kingsbury, W. D. J. Med. Chem. 1989, 32, 715.
(f) Szmuszkovicz, J.; Darlington, W. H.; Von Voigtlander,
P. F. WO 8804292 A1, ; Chem. Abstr. 1988, 110, 75335
(g) Seeman, P.; Guan, H.-C.; Nobrega, J.; Jiwa, D.;
Markstein, R.; Balk, J.-H.; Picetti, R.; Borrelli, E.; Tol, H. H.
M. V. Synapse 1997, 25, 137.
(13) (a) Moseley, J. D.; Kappe, C. O. Green Chem. 2011, 13, 794.
(b) Lidstrom, P.; Tierney, J.; Wathey, B.; Westman, J.
Tetrahedron 2001, 57, 9225.
(14) (a) Loupy, A. C. R. Chim. 2004, 7, 103. (b) Microwaves in
Organic Synthesis; Loupy, A., Ed.; Wiley-VCH: Weinheim,
2006, 2nd ed.. (c) Strauss, C. R.; Varma, R. S. Top. Curr.
Chem. 2006, 266, 199. (d) Varma, R. S. Green Chem. Lett.
Rev. 2007, 1, 37. (e) Jeselnik, M.; Varma, R. S.; Polanc, S.;
Kocevar, M. Chem. Commun. 2001, 1716. (f) Larhed, M.;
Moberg, C.; Hallberg, A. Acc. Chem. Res. 2002, 35, 717.
(15) Rodriguez, A. M.; Prieto, P.; de la Hoz, A.; Diaz-Ortiz, A.
Org. Biomol. Chem. 2011, 9, 2371.
(16) (a) Sarmah, M. M.; Sarma, R.; Prajapati, D.; Hu, W.
Tetrahedron Lett. 2013, 54, 267. (b) Sarma, R.; Sarmah, M.
M.; Prajapati, D. J. Org. Chem. 2012, 77, 2018. (c) Lekhok,
K. C.; Bhuyan, D.; Prajapati, D.; Boruah, R. C. Mol.
Diversity 2010, 14, 841. (d) Prajapati, D.; Borah, K. J.;
Gohain, M. Synlett 2007, 595. (e) Prajapati, D.; Gohain, M.;
Thakur, A. J. Bioorg. Med. Chem. Lett. 2006, 16, 3537.
(17) General Procedure
(6) (a) Jansen, O.; Akhmedjanova, V.; Angenot, L.; Balansard,
G.; Chariot, A.; Ollivier, E.; Tits, M.; Frederich, M. J.
Ethnopharmacol. 2006, 105, 241. (b) Takimoto, C. H.;
Calvo, E. Principles of Oncologic Pharmacotherapy, In
Cancer Management: A Multidisciplinary Approach;
Pazdur, R.; Wagman, L. D.; Camphausen, K. A.; Hoskins,
W. J., Eds.; Oncology Group, CMPMedica: New York,
2008, 11 ed. (c) Wall, M. E.; Wani, M. C.; Cook, C. E.;
Palmer, K. H.; McPhail, A. I.; Sim, G. A. J. Am. Chem. Soc.
1966, 88, 3888.
(7) (a) Baruah, B.; Bhuyan, P. J. Tetrahedron 2009, 65, 7099.
(b) Kalita, P. K.; Baruah, B.; Bhuyan, P. J. Tetrahedron Lett.
2006, 47, 7779. (c) Yi, C. S.; Yun, S. Y. J. Am. Chem. Soc.
2005, 127, 17000. (d) Amii, H.; Kishikawa, Y.; Uneyama,
K. Org. Lett. 2001, 3, 1109.
(8) Kundu, D.; Majee, A.; Hajra, A. Tetrahedron Lett. 2009, 50,
2668.
(9) Prajapati, D.; Bhuyan, D.; Gohain, M.; Hu, W. Mol.
Diversity 2011, 15, 257.
(10) (a) Groebke, K.; Weber, L.; Mehlin, F. Synlett 1998, 661.
(b) Verma, R. S.; Kumar, D. Tetrahedron Lett. 1999, 40,
7665.
(11) (a) Smith, B. M.; Kubczyk, T. M.; Graham, A. E.
Tetrahedron 2012, 68, 7775. (b) Smith, B. M.; Graham, A.
E. Tetrahedron Lett. 2011, 52, 6281. (c) Golden, K. C.;
Gregg, B. T.; Quinn, J. F. Tetrahedron Lett. 2010, 51, 4010.
(d) Zhang, J.; Blazecka, P. G.; Angell, P.; Lovdahl, M.;
Curran, T. T. Tetrahedron 2005, 61, 7801. (e) Ali, T.;
Chauhan, K. K.; Frost, C. G. Tetrahedron Lett. 1999, 40,
5621. (f) Chauhan, K. K.; Frost, C. G. J. Chem. Soc., Perkin
Trans. 1 2000, 3015. (g) Cintas, P. Synlett 1995, 1097.
(h) Podlech, J.; Maier, T. C. Synthesis 2003, 633. (i) Loh, T.
P.; Chua, G. L. Chem. Commun. 2006, 2739. (j) Hoppe, H.
A. F.; Lloyd-Jones, G. C.; Murray, M.; Peakman, T. M.;
Walsh, K. E. Angew. Chem. Int. Ed. 1998, 37, 1545.
(12) (a) Lekhok, K. C.; Prajapati, D.; Boruah, R. C. Synlett 2008,
655. (b) Prajapati, D.; Gohain, M. Beilstein J. Org. Chem.
2006, 2. (c) Borah, H. N.; Prajapati, D.; Boruah, R. C. Synlett
2005, 2823. (d) Prajapati, D.; Laskar, D. D.; Gogoi, B. J.;
Devi, G. Tetrahedron Lett. 2003, 44, 8725. (e) Ilias, M.;
Barman, D. C.; Prajapati, D.; Sandhu, J. S. Tetrahedron Lett.
2002, 43, 1877.
1-Naphthylamine (1, 1.0 mmol), 4-fluorobenzaldehyde (2a,
1.0 mmol), and methyl propiolate (3a, 1.2 mmol) were
irradiated in a closed vessel with In(OTf)3 (10 mol%)
without solvent in a Synthos 3000 microwave reactor at 720
W, 120 °C, and 10 bar for 8 min. The crude product mixture
was dissolved in CHCl3 and directly purified by column
chromatography eluting with EtOAc–hexane (1:9) to obtain
pure methyl-2-(4-fluorophenyl)benzo[h]quinoline-4-
carboxylate (4a).
Compound 4a: off-white solid; mp 116–117 °C. 1H NMR
(300 MHz, CDCl3): δ = 9.32–9.37 (m, 1 H, arom), 8.64 (s, 1
H, COOCH3C=CH), 7.05–7.95 (m, 9 H, arom), 3.81 (s, 3 H,
CH3). 13C NMR (75 MHz, CDCl3): δ = 168.6, 155.5, 147.1,
138.6, 136.8, 136.7, 134.5, 131.07, 131.0, 130.9, 129.1,
128.6, 127.9, 127.3, 125.2, 124.8, 124.7, 123.9, 115.3,
115.0, 52.5. IR (CHCl3): 1726.7, 1603.3, 1589.0, 1561.0,
1512.7 cm–1. GC–MS: m/z = 331 [M]+. Anal. Calcd for
C21H14FNO2: C, 76.12; H, 4.26; F, 5.73; N, 4.23; O, 9.66.
Found: C, 76.10; H, 4.20; F, 5.69; N, 4.21; O, 9.61.
(18) Zani, L.; Bolm, C. Chem. Commun. 2006, 4263; and
references cited therein.
(19) 1-Naphthylamine (1, 1.0 mmol), 4-fluorobenzaldehyde (2a,
1.0 mmol), and methyl propiolate (3a, 1.2 mmol) were
refluxed with In(OTf)3 (10 mol%) in toluene (10 mL) under
air until completion (TLC), the solvent was distilled off
under reduced pressure, and the product was purified by
column chromatography eluting with EtOAc–hexane (1:9)
to obtain pure methyl-2-(4-fluorophenyl)benzo[h]quinoline-
4-carboxylate (4a).
Synlett 2013, 24, 2245–2248
© Georg Thieme Verlag Stuttgart · New York